(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of your #1 Kind of Cap - 2What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- 3The Best 20 Photography Instagram Records to Follow
- 4‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- 5Manual for Savvy Home Lighting Framework: Lights up Your Space
- Make your choice for a definitive Christmas getaway destination!
- Swap The Amalfi Coast For This Low-Cost Ligurian Seaside Town
- German finance minister sees advantages of smartphones in schools
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- 2024's Hot Games: Must-Play Titles of the Year
- Israel explores creation of int'l force with Greece, Cyprus to deter Turkey
